Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

REFERENCES
1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer
J Clin 2003;53:5–26.
2. Visbal AL, Williams BA, Nichols FC III, et al. Gender differences in
non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed
between 1997 and 2002. Ann Thorac Surg 2004;78:209–215.
3. Fu JB, Kau TY, Severson RK, et al. Lung cancer in women: analysis
of the national Surveillance, Epidemiology, and End Results database.
Chest 2005;127:768–777.
4. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age,
smoking, histology, performance status, stage, initial treatment, and
survival. Population-based study of 20 561 cases. Ann Oncol 2002;13:
1087–1093.
5. de Perrot M, Licker M, Bouchardy C, et al. Sex differences in presentation,
management, and prognosis of patients with non-small cell lung
carcinoma. J Thorac Cardiovasc Surg 2000;119:21–26.
6. Minami H, Yoshimura M, Miyamoto Y, et al. Lung cancer in women:
sex-associated differences in survival of patients undergoing resection
for lung cancer. Chest 2000;118:1603–1609.
7. World Health Organization, International Agency for Research on
Cancer. World cancer report. Lyon, France: IARC Press, 2003.
8. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J
Clin 2006;56:106–130.
9. French SA, Perry CL, Leon GR, et al. Weight concerns, dieting behavior,
and smoking initiation among adolescents: a prospective study. Am J Public
Health 1994;84:1818–1820.
10. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J
Clin 2009;59(4):225–249. Epub 2009 May 27.
11. Ries LAG, Eisner MP, Kosary CL, et al., eds. Cancer statistics review,
1975–2002. Bethesda, MD: National Cancer Institute, 2005.
12. Ferguson MK, Skosey C, Hoffman PC, et al. Sex-associated differences
in presentation and survival in patients with lung cancer. J Clin Oncol
1990;8:1402–1407.
13. Ouellette D, Desbiens G, Emond C, et al. Lung cancer in women
compared with men: stage, treatment, and survival. Ann Thorac Surg
1998;66:1140–1143; discussion 1143–1144.
14. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann
Oncol 2005;16:481–488.
15. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and
mortality in Europe in 2006. Ann Oncol 2007 Mar;18(3):581–592.
16. Jee SH, Kim IS, Suh I, et al. Projected mortality from lung cancer in
South Korea, 1980–2004. Int J Epidemiol 1998 Jun;27(3):365–369.
17. Yang L, Parkin DM, Li LD, et al. Estimation and projection of the
national profile of cancer mortality in China: 1991–2005. Br J Cancer
2004;90: 2157–2166.
18. Chen K, Wang PP, Sun B, et al. Twenty-year secular changes in sex
specific lung cancer incidence rates in an urban Chinese population.
Lung Cancer 2006 Jan;51(1):13–19.
19. Devesa SS, Shaw GL, Blot WJ. Changing patterns of lung cancer incidence
by histological type. Cancer Epidemiol Biomarkers Prev 1991
Nov-Dec;1(1):29–34.
20. Perng DW, Perng RP, Kuo BI, et al. The variation of cell type distribution
in lung cancer: a study of 10,910 cases at a medical center in
Taiwan between 1970 and 1993. Jpn J Clin Oncol 1996 Aug;26(4):
229–233.
21. Seow A, Duffy SW, Ng TP, et al. Lung cancer among Chinese females
in Singapore 1968–1992: time trends, dialect group differences, and
implications for aetiology. Int J Epidemiol 1998 Apr;27(2):167–172.
22. Lam KY, Fu KH, Wong MP, et al. Significant changes in the distribution
of histologic types of lung cancer in Hong Kong. Pathology 1993
Apr;25(2):103–105.
23. Yoshimi I, Ohshima A, Ajiki W, et al. A comparison of trends in the
incidence rate of lung cancer by histological type in the Osaka Cancer
Registry, Japan and in the Surveillance, Epidemiology, and End Results
Program, USA. Jpn J Clin Oncol 2003 Feb;33(2):98–104.
24. Au JS, Mang OW, Foo W, et al. Time trends of lung cancer incidence
by histologic types and smoking prevalence in Hong Kong 1983–2000.
Lung Cancer 2004 Aug;45(2):143–152.
25. Jindal SK, Malik SK, Dhand R, et al. Bronchogenic carcinoma in
Northern India. Thorax 1982 May;37(5):343–347.
26. Badar F, Meerza F, Khokhar RA, et al. Characteristics of lung cancer
patients–the Shaukat Khanum Memorial experience. Asian Pac J
Cancer Prev 2006 Apr-Jun;7(2):245–248.
27. Stratton K, Shetty P, Wallace R, et al. Clearing the smoke: assessing
the science base for tobacco harm reduction. Washington DC: National
Academy Press, 2001.
28. Yu IT, Chiu YL, Au JS, et al. Dose-response relationship between cooking
fumes exposures and lung cancer among Chinese nonsmoking
women. Cancer Res 2006 May 1;66(9):4961–4967.
29. Gao YT, Blot WJ, Zheng W, et al. Lung cancer among Chinese women.
Int J Cancer 1987 Nov 15;40(5):604–609.
30. Wang TJ, Zhou BS, Shi JP. Lung cancer in nonsmoking Chinese
women: a case-control study. Lung Cancer 1996 Mar;(14 Suppl 1):
S93–S98.
31. Wu-Williams AH, Dai XD, Blot W, et al. Lung cancer among women
in north-east China. Br J Cancer 1990 Dec;62(6):982–987.
32. Ko YC, Cheng LS, Lee CH, et al. Chinese food cooking and lung cancer
in women nonsmokers. Am J Epidemiol 2000 Jan 15;151(2):140–147.
33. Metayer C, Wang Z, Kleinerman RA. Cooking oil fumes and risk
of lung cancer in women in rural Gansu, China. Lung Cancer 2002
Feb;35(2):111–117.
34. Kleinerman RA, Wang Z, Lubin J, et al. Lung cancer and indoor air
pollution in rural China. Ann Epidemiol 2000 Oct 1;10(7):469.
35. Zhong L, Goldberg MS, Gao YT, et al. Lung cancer and indoor air pollution
arising from Chinese-style cooking among nonsmoking women
living in Shanghai, China. Epidemiology 1999 Sep;10(5):488–494.
36. Seow A, Poh WT, Teh M, et al. Fumes from meat cooking and lung
cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2000
Nov;9(11):1215–1221.
37. Zhao Y, Wang S, Aunan K, et al. Air pollution and lung cancer risks in
China–a meta-analysis. Sci Total Environ 2006 Aug 1;366(2–3):500–
513. Epub 2006 Jan 10.
38. Mumford JL, He XZ, Chapman RS, et al. Lung cancer and indoor air
pollution in Xuan Wei, China. Science 1987 Jan 9;235(4785):217–220.
39. Zhou BS, Wang TJ, Guan P, et al. Indoor air pollution and pulmonary
adenocarcinoma among females: a case-control study in Shenyang,
China. Oncol Rep 2000 Nov-Dec;7(6):1253–1259.
40. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA
Cancer J Clin 2005 Mar-Apr;55(2):74–108.
41. Kurahashi N, Inoue M, Liu Y, et al. Passive smoking and lung cancer in
Japanese non-smoking women: a prospective study. Int J Cancer 2008
Feb 1;122(3):653–657.
42. Siegfried JM. Women and lung cancer: does oestrogen play a role?
Lancet Oncol 2001 Aug;2(8):506–513.
43. Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the
lung in women. J Natl Cancer Inst 1994 Jun 1;86(11):869–870.
44. Thun MJ, Henley SJ, Burns D, et al. Lung cancer death rates in lifelong
nonsmokers. J Natl Cancer Inst 2006 May 17;98(10):691–699.
45. Agudo A, Ahrens W, Benhamou E, et al. Lung cancer and cigarette
smoking in women: a multicenter case-control study in Europe. Int J
Cancer 2000 Dec 1;88(5):820–827.
46. Kreuzer M, Boffetta P, Whitley E, et al. Gender differences in lung
cancer risk by smoking: a multicentre case-control study in Germany
and Italy. Br J Cancer 2000 Jan;82(1):227–233.
47. Koyi H, Hillerdal G, Brandén E. A prospective study of a total material
of lung cancer from a county in Sweden 1997–1999: gender, symptoms,
type, stage, and smoking habits. Lung Cancer 2002 Apr;36(1):9–14.
48. Patel JD. Lung cancer in women. Clin Oncol 2005 May 10;23(14):3212–
3218. Review.
49. Zang EA, Wynder EL. Differences in lung cancer risk between men
and women: examination of the evidence. J Natl Cancer Inst 1996;88:
183–192.
50. Risch HA, Howe GR, Jain M, et al. Are female smokers at higher risk
for lung cancer than male smokers? A case control analysis by histologic
type. Am J Epidemiol 1993;138:281–293.
51. Henschke CI, Miettinen OS. Women susceptibility to tabacco carcinogens.
Lung Cancer 2004;43:1–5.
52. Yang XR, Wacholder S, Xu Z, et al. CYP1A1 and GSTM1 polymorphisms
in relation to lung cancer risk in Chinese women. Cancer Lett
2004 Oct 28;214(2):197–204.
53. Hung RJ, Boffetta P, Brockmöller J, et al. CYP1A1 and GSTM1 genetic
polymorphisms and lung cancer risk in Caucasian non-smokers:
a pooled analysis. Carcinogenesis 2003 May;24(5):875–882.
54. Raimondi S, Boffetta P, Anttila S, et al. Metabolic gene polymorphisms
and lung cancer risk in non-smokers. An update of the GSEC study.
Mutat Res 2005 Dec 30;592(1–2):45–57. Epub 2005 Jul 11.
55. Bennett WP, Alavanja MC, Blomeke B, et al. Environmental tobacco
smoke, genetic susceptibility, and risk of lung cancer in never-smoking
women. J Natl Cancer Inst 1999 Dec 1;91(23):2009–2014.
56. Kiyohara C, Wakai K, Mikami H. Risk modification by CYP1A1 and
GSTM1 polymorphisms in the association of environmental tobacco
smoke and lung cancer: a case-control study in Japanese nonsmoking
women. Int J Cancer 2003 Oct 20;107(1):139–144.
57. Chan-Yeung M, Tan-Un KC, Ip MS, et al. Lung cancer susceptibility
and polymorphisms of glutathione-S-transferase genes in Hong Kong.
Lung Cancer 2004 Aug;45(2):155–160.
58. Nitadori J, Inoue M, Iwasaki M, et al. Association between lung cancer
incidence and family history of lung cancer: data from a largescale
population-based cohort study, the JPHC study. Chest 2006
Oct;130(4):968–975.
59. Schwartz AG, Yang P, Swanson GM. Familial risk of lung cancer
among nonsmokers and their relatives. Am J Epidemiol 1996 Sep
15;144(6):554–562.
60. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell
control in early events in carcinogenesis. J Natl Cancer Inst 2000 May
3;92(9):690–698. Review.
61. Cheng YW, Chiou HL, Sheu GT, et al. The association of human
papillomavirus 16/18 infection with lung cancer among nonsmoking
Taiwanese women. Cancer Res 2001 Apr 1;61(7):2799–2803.
62. Fei Y, Yang Y, Hsieh WC, et al. Different human papillomavirus 16/18
infection in Chinese non-small cell lung cancer patients living in
Wuhan, China. Jpn J Clin Oncol 2006;36:274–279.
63. Brownson RC, Alavanja MC, Chang JC. Occupational risk factors for
lung cancer among nonsmoking women: a case-control study in Missouri
(United States). Cancer Causes Control 1993 Sep;4(5):449–454.
64. Kaufman EL, Jacobson JS, Hershman DL, et al. Effect of breast cancer
radiotherapy and cigarette smoking on risk of second primary lung
cancer. J Clin Oncol 2008 Jan 20;26(3):392–398.
65. International Agency for Research on Cancer (IARC). IARC monographs
on the evaluation of carcinogenic risks to humans. Man-made
mineral fibres and radon. Lyon, France: IARC, 1988.
66. Bonner MR, Bennett WP, Xiong W, et al. Radon, secondhand smoke,
glutathione-S-transferase M1, and lung cancer among women. Int J
Cancer 2006 Sep 15;119(6):1462–1467.
67. Alberg AJ, Samet JM. Epidemiology of lung cancer. In: Sadler MJ,
Caballero B, Strain JJ, eds. Encyclopedia of human nutrition. London,
UK: Academic Press, 2005:272–284.
68. Bond GG, Thompson FE, Cook RR. Dietary vitamin A and lung
cancer: results of a case-control study among chemical workers. Nutr
Cancer 1987;9(2–3):109–121.
69. Brennan P, Fortes C, Butler J, et al. A multicenter case-control study of
diet and lung cancer among non-smokers. Cancer Causes Control 2000
Jan;11(1):49–58.
70. Hu J, Mao Y, Dryer D, et al, and the Canadian Cancer Registries Epidemio
logy Research Group. Risk factors for lung cancer among Canadian women
who have never smoked. Cancer Detect Prev 2002;26(2):129–138.
71. Brownson RC, Alavanja MC. Previous lung disease and lung cancer
risk among women (United States). Cancer Causes Control 2000
Oct;11(9):853–858.
72. Mayne ST, Buenconsejo J, Janerich DT. Previous lung disease and risk
of lung cancer among men and women nonsmokers. Am J Epidemiol
1999 Jan 1;149(1):13–20.
73. Wu AH, Fontham ET, Reynolds P, et al. Previous lung disease and
risk of lung cancer among lifetime nonsmoking women in the United
States. Am J Epidemiol 1995 Jun 1;141(11):1023–1032.
74. Patel JD, Bach PB, Kris MG. Lung cancer in US women: a contemporary
epidemic. JAMA 2004;29:1763–1768.
75. Zang EA, Wynder EL. Differences in lung cancer risk between men
and women: Examination of the evidence. J Natl Cancer Inst 1996;88:
183–192.
76. Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in
never smokers. J Clin Oncol 2007;25:472–478.
77. Levin ER. Bidirectional signaling between the estrogen receptor and the
epidermal growth factor receptor. Mol Endocrinol 2003;17:309–317.
78. Stabile LP, Davis AL, Gubish CT, et al. Human non-small cell lung tumors
and cells derived from normal lung express both estrogen receptor
alpha and beta and show biological responses to estrogen. Cancer Res
2002;62:2141–2150.
79. Kawai H, Ishii A, Washiya K, et al. Combined overexpression of EGFR
and estrogen receptor alpha correlates with a poor outcome in lung
cancer. Anticancer Res 2005;25:4693–4698.
80. Wu CT, Chang YL, Shih JY, et al. The significance of estrogen receptor
beta in 301 surgically treated non-small cell lung cancers. J Thorac
Cardiovasc Surg 2005;130:979–986.
81. Schwartz AG, Prysak GM, Murphy V, et al. Nuclear estrogen receptor
beta in lung cancer: expression and survival differences by sex. Clin
Cancer Res 2005;11:7280–7287.
82. Skov BG, Fischer BM, Pappot H. Oestrogen receptor b over expression
in males with non-small cell lung cancer is associated with better
survival. Lung Cancer 2008;59:88–94.
83. Hershberger PA, Vasquez AC, Kanterewicz B, et al. Regulation of endogenous
gene expression in human non-small cell lung cancer cells by
estrogen receptor ligands. Cancer Res 2005;65:1598–1605.
84. Osborne CK, Yochmowitz MG, Knight WA III, et al. The value of
estrogen and progesterone receptors in the treatment of breast cancer.
Cancer 1980;46:2884–2888.
85. Thorpe SM, Rose C, Rasmussen BB, et al. Prognostic value of steroid
hormone receptors: multivariate analysis of systemically untreated
patients with node negative primary breast cancer. Cancer Res
1987;47:6126–6133.
86. O’Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic
importance of pretreatment clinical characteristics in patients with advanced
non-small-cell lung cancer treated with combination chemotherapy.
J Clin Oncol 1986;4:1604–1614.
87. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in
extensive-stage non-small-cell lung cancer: the Southwest Oncology
Group experience. J Clin Oncol 1991;9:1618–1626.
88. Moore KA, Mery CM, Jaklitsch MT, et al. Menopausal effects on presentation,
treatment, and survival of women with non-small cell lung
cancer. Ann Thorac Surg 2003;766:1789–1795.
89. Wakelee HA, Dahlberg SE, Schiller JH, et al. Menopausal status of
women may affect survival in advanced NSCLC: Analysis of recent
Eastern Cooperate Oncology Group (ECOG) studies using age of 60
years or older as a surrogate marker: P1-052. J Thorac Oncol 2007;
2:S570.
90. Ganti AK, Sahmoun AE, Panwalkar AW, et al. Hormone replacement
therapy is associated with decreased survival in women with lung cancer.
J Clin Oncol 2006;24:59–63.
91. Schabath MB, Wu X, Vassilopoulou-Sellin R, et al. Hormone replacement
therapy and lung cancer risk: a case-control analysis. Clin Cancer
Res 2004;10:113–123.
92. Schwartz AG, Wenzlaff AS, Prysak GM, et al. Reproductive factors,
hormone use, estrogen receptor expression, and risk of non-small cell
lung cancer in women. J Clin Oncol 2007;25:5785–5792.
93. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers–a different
disease. Nat Rev Cancer 2007;7:778–790.
94. Stabile LP, Lyker JS, Gubish CT, et al. Combined targeting of the estrogen
receptor and the epidermal growth factor receptor in non-small
cell lung cancer shows enhanced antiproliferative effects. Cancer Res
2005;65:1459–1470.
95. Hamilton A, Piccart M. The third-generation non-steroidal aromatase
inhibitors: a review of their clinical benefits in the second-line
hormonal treatment of advanced breast cancer. Ann Oncol 1999;10:
377–384.
96. Giudici D, Ornati G, Briatico G, et al. 6-Methylenandrosta-1,4-
diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor.
J Steroid Biochem 1988;30:391–394.
97. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention
of breast cancer: report of the National Surgical Adjuvant Breast
and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–1388.
98. Weinberg OK, Marquez-Garban DC, Fishbein MC, et al. Aromatase inhibitors
in human lung cancer therapy. Cancer Res 2005;65:11287–11291.
99. Martel C, Melner MH, Gagné D, et al. Widespread tissue distribution
of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta
5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase
and aromatase activities in the rhesus monkey. Mol Cell Endocrinol
1994;104:103–111.
100. Price T, Aitken J, Simpson ER. Relative expression of aromatase cytochrome
P450 in human fetal tissues as determined by competitive
polymerase chain reaction amplification. J Clin Endocrinol Metab
1992;74:879–883.
101. Coombes RC, Hall E, Gibson LJ, et al., and the Intergroup Exemestane
Study. A randomized trial of exemestane after two to three years of
tamoxifen therapy in postmenopausal women with primary breast cancer.
N Engl J Med 2004;35011:1081–1092.
102. Mah V, Seligson DB, Li A, et al. Aromatase expression predicts survival
in women with early-stage non small cell lung carcinoma. Cancer Res
2007;67:10484–10490.
103. Thomas P, Pang Y, Filardo EJ, et al. Identity of an estrogen membrane
receptor coupled to a G protein in human breast cancer cells.
Endocrinology 2005;146:624–632.
104. Revankar CM, Cimino DF, Sklar LA, et al. A transmembrane intracellular
estrogen receptor mediates rapid cell signaling. Science
2005;307:1625–1630.
105. Pietras RJ, Márquez-Garbán DC. Membrane-associated estrogen
receptor signaling pathways in human cancers. Clin Cancer Res
2007;13:4672–4676.
106. Rajkumar T, Gullick WJ. The type I growth factor receptors in human
breast cancer. Breast Cancer Res Treat 1994;29:3–9.
107. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network.
Nat Rev Mol Cell Biol 2001;2:127–137.
108. Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor
overexpression correlates with a poor prognosis in completely resected
non-small-cell lung cancer. Ann Oncol 2004;151:28–32.
109. Márquez-Garbán DC, Chen HW, Fishbein MC, et al. Estrogen receptor
signaling pathways in human non-small cell lung cancer. Steroids
2007;72:135–143.
110. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor
through phosphorylation by mitogen-activated protein kinase. Science
1995;270:1491–1494.
111. Yang SH, Mechanic LE, Yang P, et al. Mutations in the tyrosine kinase
domain of the epidermal growth factor receptor in non-small cell lung
cancer. Clin Cancer Res 2005;11:2106–2110.
112. Traynor AM, Schiller JH, Stabile LP, et al. Combination treatment with
gefitinib and fulvestrant for post-menopausal women with advanced
non-small cell lung cancer. ASCO Annual Meeting Proceedings. Orlando,
FL; 2005. abstract 7224.
113. Okubo S, Kurebayashi J, Otsuki T, et al. Additive antitumour effect
of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib
(Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI
182,780) in breast cancer cells. Br J Cancer 2004;901:236–244.
114. Su JM, Hsu HK, Chang H, et al. Expression of estrogen and progesterone
receptors in non-small-cell lung cancer: immunohistochemical
study. Anticancer Res 1996;16:3803–3806.
115. Kaiser U, Hofmann J, Schilli M, et al. Steroid-hormone receptors
in cell lines and tumor biopsies of human lung cancer. Int J Cancer
1996;67:357–364.
116. Di Nunno L, Larsson LG, Rinehart JJ, et al. Estrogen and progesterone
receptors in non-small cell lung cancer in 248 consecutive patients
who underwent surgical resection. Arch Pathol Lab Med 2000;124:
1467–1470.
117. Ishibashi H, Suzuki T, Suzuki S, et al. Progesterone receptor in nonsmall
cell lung cancer–a potent prognostic factor and possible target for
endocrine therapy. Cancer Res 2005;65:6450–6458.
118. Sutton G. Hormonal aspects of endometrial cancer. Curr Opin Obstet
Gynecol 1990;2:69–73.
119. Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma
of the endometrium. N Engl J Med 1961;264:216–222.
120. Moore R, Doherty D, Chamberlain R, et al. Sex differences in survival
in non-small cell lung cancer patients 1974–1998. Acta Oncol
2004;43:57–64.
121. Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage
I, II, and III non-small cell lung cancer have better survival than men.
Chest 2006;130:1796–1802.
122. Alexiou C, Onyeaka CVP, Beggs D, et al. Do women live longer
following lung resection for carcinoma? Eur J Cardiothorac Surg
2002;21:319–325.
123. Båtevik R, Grong K, Segadal L, et al. The female gender has a positive
effect on survival independent of background life expectancy
following surgical resection of primary non-small cell lung cancer:
a study of absolute and relative survival over 15 years. Lung Cancer
2005;47:173–181.
124. Hajime M, Shimao F, Hikotaro K, et al. Gender differences and smoking
affect the prognosis of patients with non-small cell lung cancer.
JTO 2007, P3-247.
125. Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: do
tumors behave differently in elderly women? J Clin Oncol 2007;25
(13):1705–1712.
126. International Early Lung Cancer Action Program Investigators.
Women’s susceptibility to tobacco carcinogens and survival after diagnosis
of lung cancer. JAMA 2006;296:180–184.
127. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in
extensive-stage non-small cell lung cancer: the Southwest Oncology
Group Experience. Am J Clin Oncol 1991;9:1618–1626.
128. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide
plus chest radiotherapy followed by surgery for stages IIIA (N2) and
IIIB non-small cell lung cancer: mature results of Southwest Oncology
Group phase II study 8805. J Clin Oncol 1995;13:1880–1992.
129. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in
advanced non-small cell lung cancer: univariate and multivariate analyses
including recursive partitioning and amalgamation algorithms in
1,052 patients. J Clin Oncol 1995;13:1221–1230.
130. O’Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic
importance of pretreatment clinical characteristics in patients with advanced
non-small-cell lung cancer treated with combination chemotherapy.
J Clin Oncol 1986;4:1604–1614.
131. Wakelee HA, Wang W, Shiller JH, et al. Survival differences by sex for patients
with advanced non-small-cell lung cancer on Eastern Cooperative
Oncology Group trial 1594. J Thorac Oncol 2007;1(5):441–446.
132. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J
Med 2002;346:92–98.
133. Mandrekar S, Schild SE, Hillman SL, et al. A pooled analysis of 11
NCCTG advanced stage non-small cell lung cancer (NSCLC) trials
reveal the importance of baseline blood counts on clinical outcomes.
J Clin Oncol 2003;21:3016–3024.
134. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational,
phase III study of docetaxel plus platinum combinations versus vinorelbine
plus cisplatin for advanced non-small-cell lung cancer: the TAX
326 study group. J Clin Oncol 2003;21:3016–3024.
135. Belani CP, von Pawel J, Pluzanska A, et al. Phase III study of
docetaxel-cisplatin (DC) or docetaxel-carboplatin (D-Cb) versus
vinorelbine-cisplatin (VC) as first line treatment in advanced nonsmall
cell lung cancer (NSCLC): analyses by gender. Lung Cancer
2006;49:S235–S236.
136. Bosken CH, Wei Q, Amos CI, et al. An analysis of DNA repair as
a determinant of survival in patients with non-small-cell lung cancer.
J Natl Cancer Inst 2002;94:1091–1099.
137. Ross H, Bonomi P, Langer C, et al. Effect of gender on outcome in
two randomized phase III trials of paclitaxel poliglumex (PPX) in
chemonaive pts with advanced NSCLC and poor performance status
(PS2). Proc Am Soc Clin Oncol 2006;24:373. Abstract 7039.
138. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized
phase II trial of gefitinnib for previously treated patients with advanced
non-small-cell lung cancer. J Clin Oncol 2003;21:2237–2246.
139. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor
of the epidermal growth factor receptor tyrosine kinase, in symptomatic
patients with non-small cell lung cancer. A randomized trial.
JAMA 2003;290:2149–2158.
140. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously
treated non-small-cell lung cancer. N Engl J Med 2005;353:123–132.
141. West H, Franklin WA, Gumerlock PH, et al. Gefitinib (ZD1839)
therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest
Oncology Group (SWOG) study S0126. Proc Am Soc Clin Oncol
2004;22:145. Abstract 7014.
142. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer:
correlation with clinical response to gefitinib therapy. Science 2004;304:
1497–1500.
143. Sandler A, Gray R, Perry MC, et al. Paclitaxel-Carboplatin alone or
with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006
Dec 14;24:2542–2550.
144. Johnson BE, Steinberg SM, Phelps R, et al. Female patients with
small cell lung cancer liver longer than male patients. Am J Med
1988;85:194–196.
145. Albain KS, Crowley JJ, LeBlanc M, et al. Determinants of improved
outcome in small-cell lung cancer: an analysis of the 2,580-
patient Southwest Oncology Group database. J Clin Oncol 1990;8:
1563–1574.